MedTrace Logo

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

NCT04912193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2395

Last updated 2021-06-03

No results posted yet for this study

Summary

The reno-protective effect of Antithrombin III (ATIII) has been well-studied in various animal studies; however, little is known about the effect of ATIII on kidney function in patients undergoing liver transplantation (LT). This study aimed to determine the association between preoperative ATIII level and postoperative acute kidney injury (AKI) after LT (post-LT AKI).

Conditions

  • Liver Transplantation and Antithrombin

Interventions

DRUG

Antithrombin III

In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-04
Primary Completion
2019-01-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912193 on ClinicalTrials.gov